Skip to main content Accessibility help
×
Home
  • Print publication year: 2008
  • Online publication date: January 2010

3 - Herpes viruses

from Section 1 - Agents

Summary

Human herpes viruses are highly successful intracellular parasites. With the exception of varicella-zoster virus (VZV), they cause asymptomatic or mildly symptomatic primary infection, establish latent infection, and persist lifelong. During the host's lifetime, they periodically reactivate and infect other susceptible individuals. As long as the host's immune system is not compromised, the balance between virus and host is maintained. However, immunosuppression induced by disease or therapy can alter the balance between virus and host, resulting in systemic virus infection and concomitant disease.

The human Herpesviridae includes three subfamilies (see Table 3.1). Transmission by transfusion does not appear to occur with herpes simplex virus (HSV) or VZV. Cytomegalovirus (CMV) is by far the most important herpes virus in transfusion medicine, and its relative significance increased greatly in the last two decades, due to increases in bone marrow transplantation, solid-organ transplantation and more aggressive chemotherapy for malignant disease. This chapter reviews the role of CMV and Epstein-Barr Virus (EBV) in transfusion medicine. Human herpes viruses 6, 7, and 8 (HHV-6, HHV-7, and HHV-8) are reviewed briefly but are covered in detail in the chapter on newly identified agents (Please refer to Chapter 28).

Cytomegalovirus

Transfusion-acquired CMV infection has been the subject of numerous reviews (Blajchman et al., 2001; Gunter and Luban, 1996; Hillyer et al., 1994; Pamphilon et al., 1999b; Preiksaitis, 2000; Tegtmeier, 1989; 2001; Wong and Luban, 2002).

REFERENCES
Ablashi, D. V., Berneman, Z. N., Kramarsky, B., et al. (1995) Human herpes virus-7 (HHV-7): current status. Clin Diagn Virol, 4, 1–13.
Aboulafia, D., Mathisen, G. and Mitsuyasu, R. (1991) Case report: Aggressive Kaposi's sarcoma and Campylobacter bacteremia in a female with transfusion-associated AIDS. Am J Med Sci, 301, 256–8.
Adams, M. R., Fisher, D. M., Dumont, L. J., et al. (2000) Detecting failed WBC-reduction processes: computer simulations of intermittent and continuous process failure. Transfusion, 40, 1427–33.
Adams, P. T., Davenport, R. D., Reardon, D. A., et al. (1992) Detection of circulating donor white blood cells in patients receiving multiple transfusions. Blood, 80, 551–5.
Adler, S. P. and McVoy, M. M. (1989) Cytomegalovirus infections in seropositive patients after transfusion. Transfusion, 29, 667–71.
Adler, S. P., Baggett, J. and McVoy, M. (1985a) Transfusion-associated cytomegalovirus infections in seropositive cardiac-surgery patients. Lancet, 2, 743–6.
Adler, S. P., Chandrika, T., Lawrence, L., et al. (1983) Cytomegalovirus infections in neonates acquired by blood transfusions. Pediatr Infect Dis J, 2, 114–18.
Adler, S. P., McVoy, M. and Biro, V. G. (1985b) Detection of cytomegalovirus antibody with latex agglutination. J Clin Microbiol, 22, 68–70.
Alfieri, C., Tanner, J., Carpentier, L., et al. (1996) EBV transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient blood and oropharynx. Blood, 87, 812–817.
Anagnostopoulos, I., Hummel, M., Kreschel, C., et al., (1995) Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood, 85, 744–50.
Asano, Y., Yoshikawa, T., Suga, S., et al. (1991) Reactivation of herpes virus type 6 in children receiving bone marrow transplants for leukemia. N Engl J Med, 324, 634–635.
Atkinson, J., Edlin, B. R., Engels, E. A., et al. (2003) Seroprevalence of human herpes virus 8 among injection drug users in San Francisco. J Infect Dis, 187, 974–81.
Babcock, G. J., Decker, L. L., Volk, M., et al. (1998) EBV persistence in memory B-cells in vivo. Immunity, 9, 395–404.
Bale, J. F. Jr., Kealey, G. P., Massanari, R. M., et al. (1990) The epidemiology of cytomegalovirus infection among patients with burns. Infect Control Hosp Epidemiol, 11, 17–22.
Baumgartner, J. D., Glauser, M. P., Burgo-Black, A. L., et al. (1982) Severe cytomegalovirus infection in multiply transfused, splenectomized, trauma patients. Lancet, 2, 63–6.
Beckwith, D. G., Halstead, D. C., Alpaugh, K., et al. (1985) Comparison of a latex agglutination test with five other methods for determining the presence of antibody against cytomegalovirus. J Clin Microbiol, 21, 328–31.
Bendsoe, N., Dictor, M., Blomberg, J., et al. (1990) Increased incidence of Kaposi sarcoma in Sweden before the AIDS epidemic. Eur J Cancer, 26, 699–702.
Beneke, J. S., Tegtmeier, G. E., Alter, H. J., et al. (1984) Relation of titers of antibodies to CMV in blood donors to the transmission of cytomegalovirus infection. J Infect Dis, 150, 883–8.
Blackbourn, D. J., Ambroziak, J., Lennette, E., et al. (1997) Infectious human herpes virus 8 in a healthy North American blood donor. Lancet, 349, 609–11.
Blacklow, N. R., Watson, B. K., Miller, G., et al. (1971) Mononucleosis with heterophil antibodies and EB virus infection: acquisition by an elderly patient in hospital. Am J Med, 51, 549–52.
Blajchman, M. A. and Vamvakas, E. C. (2006) The continuing risk of transfusion-transmitted infections. N Eng J Med, 355, 1303–5.
Blajchman, M. A., Goldman, M., Freedman, J. F., et al. (2001) Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction. Transfus Med Rev, 15, 1–20.
Boeckh, M., Bowden, R. A., Gooley, T., et al. (1999) Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood, 93, 1781–2.
Booth, J. C., Hannington, G., Bakir, T. M. F., et al. (1982) Comparison of enzyme linked immunoabsorbent assay, radio-immunoassay, complement function, anti-complement immunofluorescence and passive hemagglutination techniques for detecting cytomegalovirus IG antibody. J Clin Pathol, 35, 1345–8.
Bowden, R. and Sayers, M. (1990) The risk of transmitting cytomegalovirus infection by fresh frozen plasma. Transfusion, 30, 762–3.
Bowden, R. A., Sayers, M. H., Cays, M., et al. (1989) The role of blood product filtration in the prevention of transfusion-associated cytomegalovirus (CMV) infection after marrow transplant. Transfusion, 29 (Suppl. 1), 57S.
Bowden, R. A., Sayers, M., Flournoy, N., et al. (1986) Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Eng J Med, 314, 1006–10.
Bowden, R. A., Sayers, M., Gleaves, C. A., et al. (1987) Cytomegalovirus-seronegative blood components for the prevention of primary cytomegalovirus infection after marrow transplantation: considerations for blood banks. Transfusion, 27, 478.
Bowden, R. A., Slichter, S. J., Sayers, M. H., et al. (1991) Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood, 79, 246–50.
Bowden, R. A., Slichter, S. J., Sayers, M. H., et al. (1995) A comparison of filtered leukocyte reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood, 86, 3598–606.
Brady, M. T., Milam, J. D., Anderson, D. C., et al. (1984) Use of deglycerolized red blood cells to prevent post-transfusion infection with cytomegalovirus in neonates. J Infect Dis, 150, 334–9.
Bruggerman, C. A. (1991) Reactivation of latent CMV in the rat. Transplant Proc, 23 (Suppl.3), 22–4.
Busch, M. P. and Lee, T. H. (1995) Role of donor leukocytes and leukodepletion in transfusion-associated viral infections. In Clinical Benefits of Leukodepleted Blood Products, eds Sweeney, J. and Heaton, W. A., pp. 97–112. Austin, TX, R.G. Landes Co.
Cannon, M. J., Dollard, S. C., Smith, D. K., et al. (2001) Blood-borne and sexual transmission of human herpes virus 8 in women with or at risk for human immunodeficiency virus infection. N Eng J Med, 344, 637–43.
Cannon, M. J., Laney, A. S. and Pellett, P. E. (2003) Human herpes virus 8: current issues. Clin Infect Dis, 37, 82–7.
Chandler, S. H., Handsfield, H. H. and McDougall, J. K. (1987) Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted diseases. J Infect Dis, 155, 655–60.
Cheung, K. S. and Lang, D. J. (1977) Transmission and activation of cytomegalovirus with blood transfusion: a mouse model. J Infect Dis, 135, 841–5.
Chou, S. (1986) Acquisition of donor strains of cytomegalovirus by renal transplant recipients. N Eng J Med, 314, 1418–23.
Chou, S. (1987) Cytomegalovirus infection and reinfection transmitted by heart transplantation. J Infect Dis, 155, 1054–5.
Chou, S. (1989) Neutralizing antibody responses to reinfecting strains of cytomegalovirus transplant patients. J Infect Dis, 160, 16–21.
Chou, S. and Kim, D. Y. (1987) Transmission of cytomegalovirus by pre-transplant leukocyte transfusions in renal transplant candidates. J Infect Dis, 155, 565–67.
Cockerill, F. R., Hurley, D. V., Miglagelada, J. R., et al. (1986) Polymicrobial cholangitis and Kaposi's sarcoma in blood product transfusion-related acquired immune deficiency syndrome. Am J Med, 80, 1237–41.
Collier, A., Kalish, L., Busch, M., et al. (2001) Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection. JAMA, 285, 1592–601.
Cone, R. W., Hackman, R. C., Huang, M.-L. W., et al. (1993) Human herpes virus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Eng J Med, 329, 156–61.
Cone, R. W., Huang, M.-L. W., Corey, L., et al. (1999) Human herpes virus 6 infections after bone marrow transplantation: clinical and virologic manifestations. J Infect Dis, 179, 311–8.
Curtsinger, L. J., Cheadle, W. G., Hershman, M. J., et al. (1989) Association of cytomegalovirus infection with increased morbidity is independent of transfusion. Am J Surg, 158, 606–10.
Graan-Hentzen, Y. C. E., Gratama, J. W., Mudde, G. C., et al. (1989) Prevention of primary cytomegalovirus infection in patients with hematologic malignancy by intensive white cell depletion of blood products. Transfusion, 29, 757–60.
Demmler, G. J., Brady, M. T., Bijou, H., et al. (1986) Post-transfusion cytomegalovirus infection in neonates: role of saline-washed red blood cells. J Pediatr, 108, 762–5.
Dewhurst, S., Skrincosky, D. and Loon, N. (1997a) (5 Nov) Human herpes virus 6. Expert Rev Mol Med, pp. 1–17.
Dewhurst, S., Skrincosky, D. and Loon, N.(1997b) (18 Nov) Human herpes virus 7. Expert Rev Mol Med, pp. 1–10.
DeWitte, T., Schattenberg, A., Dijk, B. A., et al. (1990) Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus unscreened blood bank donors. Transplantation, 50, 964–8.
Diamond, C., Thiede, H., Perdue, T., et al. (2001) Seroepidemiology of human herpes virus 8 among young men who have sex with men. The Seattle Young Men's Survey Team. Sex Transm Dis, 28, 176–83.
Diosi, P., Moldovan, E. and Tomescu, N. (1969) Latent cytomegalovirus infection in blood donors. Br Med J, 4, 660–2.
Dollard, S. C., Nelson, K. E., Ness, P. M., et al. (2005) Possible transmission of human herpes virus 8 by blood transfusion in a historical United States cohort. Transfusion, 45, 500–3.
Drew, N. L. and Minor, R. C. (1982) Transfusion-related cytomegalovirus infection following noncardiac surgery. JAMA, 247, 2389–91.
Drew, W. L., Tegtmeier, G. E., Alter, H. J., et al. (2003) Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion, 43, 309–13.
Drobyski, W. R., Knox, K. K., Majewski, D., et al. (1994) Brief report: fatal encephalitis due to variant B human herpes virus-6 infection in a bone marrow-transplant recipient. N Eng J Med, 330, 1356–60.
Dukers, N. H. T. M. and Rezza, G. (2003) Human herpes virus 8 epidemiology: what we do and do not know. AIDS, 17, 1717–30.
Dumont, L. J., Janos, L., VandenBroeke, T., et al. (2001) The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: a comparison of apheresis and filtration methods. Blood, 97, 3640–7.
Dworsky, M. E., Welch, K., Cassady, G., et al. (1983) Occupational risk of primary cytomegalovirus infection among pediatric health-care workers. N Eng J Med, 309, 950–3.
Dzik, W. H. (1994) Mononuclear cell microchimerism and the immunomodulatory effect of transfusion. Transfusion, 34, 1007.
Enbom, M., Urassa, W., Massambu, C., et al. (2002) Detection of human herpes virus 8 DNA in serum from blood donors with HHV-8 antibodies indicates possible blood borne virus transmission. J Med Virol, 68, 264–67.
Engelhard, D., Weinberg, M., Or, R., et al. (1991) Immunoglobulins A, G, and M to cytomegalovirus during recurrent infection in recipients of allogeneic bone marrow transplantation. J Infect Dis, 163, 628–30.
Engels, E. A., Eastman, H., Ablashi, D. V., et al. (1999) Risk of transfusion-associated transmission of human herpes virus 8. J Natl Cancer Inst, 91, 1773–5.
Evans, D. G. R. and Lyon, A. J. (1991) Fatal congenital cytomegalovirus infection acquired by an intra-uterine transfusion. Eur J Pediatr, 150, 780–1.
Friedman-Kien, A. E., Saltzman, B. R., Cao, Y., et al. (1990) Kaposi's sarcoma in HIV-negative homosexual men. Lancet, 335, 168–9.
Furukawa, T., Funamoto, Y., Ishida, S., et al. (1987) The importance of primary cytomegalovirus infection in childhood cancer. Eur J Pediatr, 146, 34–7.
Galea, G. and Urbaniak, S. J. (1992) The incidence and consequences of cytomegalovirus transmission via blood transfusion to low birthweight, premature infants in North East Scotland. Vox Sang, 62, 200–7.
Gerber, P., Walsh, J. H., Rosenblum, E. N., et al. (1969) Association of EB-virus infection with the post-perfusion syndrome. Lancet, 1, 593–6.
Gerna, G., Zipeto, D., Percivalle, E., et al. (1992) Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients. J Infect Dis, 166, 1236–44.
Gilbert, G. L., Hayes, K., Hudson, I. L., et al. (1989) Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leukocytes. Neonatal Cytomegalovirus Infection Study Group. Lancet, 1, 1228–31.
Gleaves, C. A., Smith, T. F., Schuster, E. A., et al. (1984) Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J Clin Microbiol, 19, 917–9.
Goedert, J. J., Charurat, M., Blattner, W. A., et al. (2003) Risk factors for Kaposi's sarcoma-associated herpes virus infection among HIV-1 infected pregnant women in the USA. AIDS, 17, 425–33.
Grattan, M. T., Moreno-Cabral, E., Starnes, V. A., et al. (1989) Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA, 261, 3561–66.
Griffin, M. P., O'Shea, M., Brazy, J. E., et al. (1988) Cytomegalovirus infection in a neonatal intensive care unit. Am J Dis Child, 142, 1188–93.
Grundy, J. E., Super, M., Sweny, P., et al. (1988) Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet, 2, 132–5.
Gunter, K. C., and Luban, N. L. (1996) Transfusion-transmitted cytomegalovirus and Epstein-Barr virus diseases. In Principles of Transfusion Medicine, eds Rossi, E. C., Simon, T. L., Moss, G. S. and Gould, S. A., 2nd edn, pp. 717–31. Baltimore, MD, Williams & Wilkins
Hahn, G., Jores, R. and Mocarski, E. S. (1998) Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci, 95, 3937–42.
Henle, W. and Henle, G. (1985) Epstein-Barr virus and blood transfusion. In Infection, Immunity and Blood Transfusion, eds Dodd, R. Y. and Barker, L. F., pp. 201–209. New York, Alan R. Liss.
Henle, W., Henle, G., Scriba, M., et al. (1970) Antibody responses to the Epstein-Barr virus and cytomegalovirus after open-heart and other surgery. N Eng J Med, 282, 1068–74.
Hersman, J., Meyers, J. D., Thomas, E. D., et al. (1982) The effect of granulocyte transfusions on the incidence of cytomegalovirus infection after marrow transplantation. Ann Intern Med, 96, 149–52.
Hillyer, C. D., Lankford, K. V., Roback, J. D., et al. (1999) Transfusion of the HIV-seropositive patient: immunomodulation viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5), and HHV-6, 7, and 8. Transfus Med Rev, 13, 1–17.
Hillyer, C. D, Roback, J. D., Saakadze, N., et al. (2003) Transfusion-transmitted cytomegalovirus (CMV) infection: elucidation of role and dose of monocytes in a murine model. Blood, 102, 57a(Abstract no. 189).
Hillyer, C. D., Snydman, D. R. and Berkman, E. M. (1994) The risk of cytomegalovirus infection in solid organ and bone marrow transplant recipients: transfusion of blood products. Transfusion, 30, 659–66.
Hladik, W., Dollard, S. C., Mermin, J., et al. (2006) Transmission of human herpes virus 8 by blood transfusion. N Eng J Med, 355, 1331–38.
Ho, M. (1982) Human cytomegalovirus infections in immunosuppressed patients. In Cytomegalovirus, Biology and Infection, eds Greenough, W. M. and Merigan, T. C., pp. 171–204. New York, NY, Plenum.
Hodinka, R. L. (2003) Human Cytomegalovirus. In Manual of Clinical Microbiology, eds Murray, P. R., Baron, E. J., Jorgensen, J. H., Pfaller, M. A. and Yolken, R. H., 8th edn, pp. 1304–18. Washington, DC, American Society of Microbiology Press.
Hudnall, S. D., Chen, T., Rady, P., et al. (2003) Human herpes virus 8 seroprevalence and viral load in healthy adult blood donors. Transfusion, 43, 85–90.
Hutchinson, D. L., Turner, J. H. and Schlesinger, E. R. (1971) Persistence of donor cells in neonates after fetal and exchange transfusion. Am J Obstet Gynecol, 109, 281–4.
Jacobs, R. F. (1986) Frozen deglycerolized blood and transmission of Epstein-Barr virus. J Infect Dis, 153, 800.
James, D. J., Sikotra, S., Sivakumaran, M., et al. (1997) The presence of free infectious cytomegalovirus (CMV) in the plasma of donated CMV-seropositive blood and platelets. Transfus Med, 7, 123–6.
Kane, R. C., Rousseau, W. E., Noble, G. R., et al. (1975) Cytomegalovirus infection in a volunteer blood donor population. Infect Immun, 11, 719–23.
Kapsenberg, J. G., Langenhuysen, M. M. A. C., Nieweg, H. O., et al. (1970) Post-transfusion mononucleosis with heterophil antibodies. Acta Med Scand, 187, 79–82.
Kealey, G. P., Bale, J. F., Strauss, R. G., et al. (1987) Cytomegalovirus infection in burn patients. J Burn Care Rehabil, 8, 543–5.
Kozireva, S., Nemceva, G., Ganilane, I., et al. (2001) Prevalence of blood-borne viral infections (cytomegalovirus, human herpes virus-6, human herpes virus-7, human herpes virus-8, human T-cell lymphotropic virus-I/II, human retrovirus-5) among blood donors in Latvia. Ann Hematol, 80, 669–73
Krech, U. (1973) Complement-fixing antibodies against cytomegalovirus in different parts of the world. Bull WHO, 49, 103–6.
Kreel, I., Zarroff, L. I. and Canter, J. W. (1960) A syndrome following total body perfusion. Surg Gynecol Obstet, 111, 317–21.
Kumar, A., Nankervis, G. A., Cooper, R. A., et al. (1980) Acquisition of cytomegalovirus infection in infants following exchange transfusion: a prospective study. Transfusion, 20, 327–31.
Lamberson, H. V., McMillan, J. A., Weiner, L. B., et al. (1988) Prevention of transfusion-associated cytomegalovirus (CMV) infection in neonates by screening blood donors for IgM to CMV. J Infect Dis, 157, 820–3.
Landaw, E. M., Kanter, M. and Petz, L. D. (1996) Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection. Blood, 87, 4910.
Landry, M. L., Ferguson, D., Stevens-Ayers, T., et al. (1996) Evaluation of CMV Brite kit for detection of cytomegalovirus pp65 antigenemia in peripheral blood leukocytes by immunofluorescence. J Clin Microbiol, 34, 1337–39.
Laupacis, A., Brown, J., Costello, B., et al. (2001) Prevention of post-transfusion CMV in the era of universal leukoreduction: a consensus statement. Transfusion, 41, 560–69.
Lee, T-H., Paglieroni, T., Ohto, H., et al. (1999) Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients. Blood, 93, 3127–39.
Lentz, E. B., Dock, N. L., McMahon, C. A., et al. (1988) Detection of antibody to cytomegalovirus-induced early antigens and comparison with four serologic assays and presence of viruria in blood donors. J Clin Microbiol, 26, 133–5.
Linde, A. (2003) Epstein-Barr Virus. In Manual of Clinical Microbiology, 8th edn, eds Murray, P. R., Baron, E. J., Jorgensen, J. H., Pfaller, M. A. and Yolken, R. H., pp. 1331–40. Washington, DC, American Society of Microbiology Press.
Luppi, M., Barozzi, P., Guaraldi, G., et al. (2003) Human herpes virus 8 associated diseases in solid-organ transplantation: importance of viral transmission from the donor. Clin Infect Dis, 37, 606–607.
Luthardt, T., Siebert, H., Lösel, I., et al. (1971) Cytomegalovirus-infektionen bei Kindern mit Blutaustausch-transfusion im Neugeborenenalter. Klin Wochenschr, 49, 81–6.
MacKinnon, S., Burnett, A. K., Crawford, R. J., et al. (1988) Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation. J Clin Pathol, 41, 948–50.
Malloy, D. and Lipton, K. S. (2002) Update on Provision of CMV-reduced-risk Cellular Blood Components. Association Bulletin no. 02–4. Bethesda, MD, American Association of Blood Banks.
Manez, R., Kusne, S., Martin, M., et al. (1993) The impact of blood transfusion on the occurrence of pneumonitis in primary cytomegalovirus infection after liver transplantation. Transfusion, 33, 594–7.
Masucci, M. G. and Ernberg, I. (1994) Epstein-Barr virus: adaptation to a life within the immune system. Trends Microbiol, 2, 125–130.
Mayo, D., Armstrong, J. A. and Ho, M. (1978) Activation of latent murine cytomegalovirus infection: cocultivation, cell transfer, and the effect of immunosuppression. J Infect Dis, 138, 890–96.
Mbulaiteye, S. M., Biggar, R. J., Bakaki, P. M., et al. (2003) Human herpes virus 8 infection and transfusion history in children with sickle-cell disease in Uganda. J Natl Cancer Inst, 95, 1330–35.
McCracken, G. H., Shinefield, H. R., Cobb, K., et al. (1969) Congenital cytomegalic inclusion disease. Am J Dis Child, 117, 522–39.
McCullough, J., Yunis, E. J., Benson, S. J., et al. (1969) Effect of blood bank storage on leukocyte function. Lancet, 1, 1333.
McEnery, G. and Stern, H. (1970) Cytomegalovirus infection in early infancy: five atypical cases. Arch Dis Child, 45, 669–73.
McMonigal, M., Horwitz, C. A., Henle, W., et al. (1983) Post-perfusion syndrome due to Epstein-Barr virus: report of two cases and review of the literature. Transfusion, 23, 331–5.
Meyers, J. D., Flournoy, N. and Thomas, E. D. (1986) Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis, 153, 478–88.
Miller, W. J., McCullough, J., Balfour, H. H. Jr., et al. (1991) Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant, 7, 227–34.
Mirkovic, R., Werch, J., South, M. A., et al. (1971) Incidence of cytomegaloviremia in blood bank donors and in infants with congenital cytomegalic inclusion disease. Infect Immun, 3, 45–50.
Monif, G. R. G., Daicoff, G. I. and Flory, L. F. (1976) Blood as a potential vehicle for the cytomegaloviruses. Am J Obstet Gynecol, 126, 445–8.
Murphy, M. F., Grint, P. C., Hardiman, A. E., et al. (1988) Use of leukocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukemia. Br J Hematol, 70, 253–4.
Narvios, A. B., Przepiorka, D., Tarrand, J., et al. (1998) Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients. Bone Marrow Transplant, 22, 575–7.
Nelson, K. E., Dovaid, S. C., Cannon, M. J., et al. (2004) Probable transmission of human herpes virus 8 (HHV-8) by blood transfusion among cardiac surgery patients. Transfusion, 44(Suppl.), 96A.
Nichols, W. G., Price, T. H., Gooley, T., et al. (2003) Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood, 101, 4195–00.
Nielsen, H. J., Skov, F., Dybkjaer, E., et al. (1997) Leucocyte and platelet-derived bioactive substances in stored blood: effect of prestorage leucocyte filtration. Eur J Haematol, 58, 273–8.
Ohto, H., Ujiie, N. and Hirai, H. (1999) Lack of difference in cytomegalovirus transmissions via the transfusion of filtered-irradiated and nonfiltered-irradiated blood to newborn infants in an endemic area. Transfusion, 39, 201–5.
Olding, L. B., Jensen, F. C. and Oldstone, M. B. (1975) Pathogenesis of cytomegalovirus infection: 1. Activation of virus from bone marrow derived lymphocytes by in vitro allogeneic reaction. J Exp Med, 141, 561–572.
Operskalski, E. A., Busch, M. P., Mosley, J. W., et al. (1997) Blood donations and viruses. Lancet, 349, 1327–31.
Padilla, S., Rivera-Perlman, Z. and Solomon, L. (1990) Kaposi's sarcoma in transfusion-associated acquired immunodeficiency syndrome. Arch Pathol Lab Med, 114, 40–42.
Paloheimo, J. A., Essen, R., Klemola, E., et al. (1968) Subclinical cytomegalovirus infections and cytomegalovirus mononucleosis after open heart surgery. Am J Cardiol, 22, 624–30.
Pamphilon, D. H., Foot, A. B. M., Adeodu, A., et al. (1999a) Prophylaxis and prevention of CMV infection in BM allograft recipients: leukodepleted platelets are equivalent to those from CMV-seronegative donors. Bone Marrow Transplant 23(Suppl. 1), S66.
Pamphilon, D. H., Rider, J. R., Barbara, J. A. J., et al. (1999b) Prevention of transfusion-transmitted cytomegalovirus infection. Transf Med, 9, 115–23.
Papaevangelou, G., Economidou, J., Roumetiotou, A., et al. (1979) Epstein-Barr infection in polytransfused patients with homozygous β-thalassaemia. Vox Sang, 37, 305–9.
Pass, M. A., Johnson, J. D., Schulman, I. A., et al. (1976) Evaluation of a walking-donor blood transfusion program with intensive care nursery. J Pediatr, 89, 646–51.
Pearson, H. A., Wood, C., Andeman, W., et al. (1986) Low risk of hepatitis B from blood transfusions in thalassaemic patients in Connecticut. J Pediatr, 108, 252–3.
Pellett, P. E., Wright, D. J., Engels, E. A., et al. (2003) Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion, 43, 1260–68.
Perham, T. G. M., Carl, E. W., Conway, P. J., et al. (1971) Cytomegalovirus infection in blood donors – a prospective study. Br J Haematol, 20, 307–20.
Phipps, P. H., Gregoire, L., Rossier, E., et al. (1983) Comparison of five methods of cytomegalovirus antibody screening of blood donors. J Clin Microbiol, 18, 1296–300.
Preiksaitis, J. K. (1991) Indications for the use of cytomegalovirus-seronegative blood products. Transfus Med Rev, 5, 1–17.
Preiksaitis, J. K. (2000) The Cytomegalovirus-‘safe’ blood product: is leukoreduction equivalent to antibody screening? Transf Med Rev, 14, 112–36.
Preiksaitis, J. K. (2003) Prevention of transfusion-acquired CMV infection: is there a role for NAT? Transfusion, 43, 302–5.
Preiksaitis, J. K., Brown, L. and McKenzie, M. (1988b) The risk of cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression. J Infect Dis, 157, 523–9.
Preiksaitis, J. K., Brown, L., McKenzie, M., et al. (1988a) Transfusion-acquired cytomegalovirus infection in neonates: a prospective study. Transfusion, 28, 205–9.
Preiksaitis, J. K., Desai, S., Vaudry, W., et al. (1997) Transfusion-and community-acquired cytomegalovirus infection in children with malignant disease: a prospective study. Transfusion, 37, 941–6.
Preiksaitis, J. K., Rosno, S., Grumet, C., et al. (1983) Infections due to herpes viruses in cardiac transplant recipients: role of the donor heart and immunosuppressive therapy. J Infect Dis, 147, 974.
Preiksaitis, J. K., Sandhu, J. and Strautman, M. (2002) The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center. Transfusion, 42, 396–402.
Purcell, R. H., Walsh, J. H., Holland, P. V., et al. (1971) Seroepidemiological studies of transfusion-associated hepatitis. J Infect Dis, 123, 406–13.
Purtilo, D. T., Paquin, L. A., Sakamoto, K., et al. (1980) Persistent transfusion-associated infectious mononucleosis with transient acquired immunodeficiency. Am J Med, 68, 437–40.
Qu, L., Xu, S., Rowe, D. and Triulzi, D. (2005) Efficacy of Epstein-Barr virus removal by leukoreduction of red blood cells. Transfusion, 45, 591–5.
Rader, D. C., Nucha, P., Moore, S. B., et al. (1985) Cytomegalovirus infection in patients undergoing non-cardiac surgical procedures. Surg Gynecol Obstet, 160, 13–6.
Ratko, A., Cummings, J. P., Oberman, H., et al. (2001) Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion, 41, 1310–19.
Ratnamohan, V. M., Chapman, J., Howse, H., et al. (1998) Cytomegalovirus and human herpes virus 6 both cause viral disease after renal transplantation. Transplantation, 66, 877–82.
Ratnamohan, V. M., Mathys, J. M., McKenzie, A., et al. (1992) HCMV-DNA is detected more frequently than infectious virus in blood leukocytes of immunocompromised patients: a direct comparison of culture-immunofluorescence and PCR for detection of HCMV in clinical specimens. J Med Virol, 38, 252–9.
Revello, M. G., Zavattoni, M., Sarasini, A., et al. (1998) Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy. J Infect Dis, 177, 1170–75.
Roback, J. D., Drew, W. L., Laycock, M. E., et al. (2003) CMV DNA is rarely detected in healthy blood donors using validated PCR assays. Transfusion, 43, 314–21.
Roback, J. D., Hillyer, C. D., Drew, W. L., et al. (2001) Multicenter evaluation of PCR methods for detecting CMV DNA in blood donors. Transfusion, 41, 1249–57.
Roujeau, J. C., Brun-Buisson, C., Penso, D., et al. (1988) Non-acquired immune deficiency syndrome-related Kaposi's sarcoma after severe infection. J Am Acad Dermatol, 18, 378.
Rubin, R. H., Tolkoff-Rubin, N. E., Oliver, D., et al. (1985) Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation, 40, 243–9.
Salahuddin, S. Z., Ablashi, D. V., Markham, P. D., et al. (1986) Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science, 234, 596–601.
Sayers, M. H. (1994) Transfusion-transmitted viral infections other than hepatitis and human immunodeficiency virus infection. Cytomegalovirus, Epstein-Barr virus, human herpesvirus 6, and human parvovirus B19. Arch Pathol Lab Med, 118, 346–9.
Sherman, M. E. and Dzik, W. H. (1988) Stability of antigens in leukocytes in banked platelet concentrates: decline in HLA-DR antigen expression and mixed lymphocyte culture stimulating capacity following storage. Blood, 72, 867–72.
Sloand, E., Kumar, P., Klein, H. G., et al. (1994) Transfusion of blood components to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection. Transfusion, 34, 48–53.
Smith, D. M. Jr. (1997) Leukocyte reduction for the Prevention of Transfusion-transmitted Cytomegalovirus (TT-CMV). Association Bulletin no. 97–2. Bethesda, MD, American Association of Blood Banks.
Snydman, D. R., Werner, B. G., Meissner, H. C., et al. (1995) Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates. Pediatr Infect Dis J, 14, 34–40.
Soderberg-Naucler, C., Fish, K. N. and Nelson, J. A. (1997) Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell, 91, 119–26.
Solem, J. H. and Jörgensen, W. (1969) Accidentally transmitted infectious mononucleosis. Acta Med Scan, 186–433.
Spector, S. A., Kirata, K. K. and Newman, T. R. (1984) Identification of multiple cytomegalovirus strains in homosexual men with acquired immunodeficiency syndrome. J Infect Dis, 150, 953–6.
Stagno, S. and Cloud, G. A. (1994) Working parents: the impact of day care and breast-feeding on cytomegalovirus infections in offspring. Proc Natl Acad Sci, 91, 2384–89.
Stanier, P., Taylor, D. L., Kitchen, A. D., et al. (1989) Persistence of cytomegalovirus in mononuclear cells in peripheral blood from blood donors. Br Med J, 299, 897–8.
Stevens, D. P., Barker, L. F., Ketcham, A. S., et al. (1979) Asymptomatic cytomegalovirus infection following blood transfusion in tumor surgery. JAMA, 211, 1341–44.
Taswell, H. F., Reisner, R. K, Rabe, D. E., et al. (1986) Comparison of three methods for detecting antibody to cytomegalovirus. Transfusion, 26, 285–9.
Tattevin, P., Cremieux, A. C., Descamps, D., et al. (2002) Transfusion-related infectious mononucleosis. Scand J Infect Dis, 34, 777–8.
Taylor-Wiedeman, J., Sissons, J. G. P., Borysiewicz, L. K., et al. (1991) Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol, 72, 2059–64.
Tegtmeier, G. E. (1986) Transfusion-transmitted cytomegalovirus infections: significance and control. Vox Sang, 51(Suppl. 1): 30–33.
Tegtmeier, G. E. (1989) Post-transfusion cytomegalovirus infections. Arch Pathol Lab Med, 113, 236–45.
Tegtmeier, G. E. (2001) Transfusion-acquired cytomegalovirus infection: Approaching resolution. In Blood Safety and Surveillance, eds Linden, J. V. and Bianco, C., pp. 315–33. New York, NY, Marcel Dekker, Inc.
Tobin, J. O. H., MacDonald, H. and Brayshay, M. (1975) Cytomegalovirus infection and exchange transfusion (letter). Br Med J, 2, 404.
Turner, A. R., MacDonald, R. N. and Cooper, B. A. (1972) Transmission of infectious mononucleosis by transfusion of pre-illness plasma. Ann Intern Med, 77, 751–3.
Urushibara, N., Kwon, K.-W., Takahashi, T. A., et al. (1995) Human cytomegalovirus DNA is not detectable with nested double polymerase chain reaction in healthy blood donors. Vox Sang, 68, 9–14.
Vamvakas, E. (2005) Is white-blood-cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev, 19, 181–99.
Vamvakas, E. and Kaplan, H. S. (1993) Early transfusion and length of survival in acquired immune deficiency syndrome: experience with a population receiving medical care at a public hospital. Transfusion, 33, 111–8.
Vamvakas, E. and Kaplan, H. S. (1994) Blood transfusion to AIDS patients: relationship to opportunistic infection. Transfusion, 34, 740.
Prooijen, H. C., Visser, J. J., Oostendorp, W. R., et al. (1994) Prevention of primary transfusion-associated CMV infection after marrow transplant recipients by the removal of white cells from blood components with high affinity filters. Br J Haematol, 87, 144–7.
Velez-Garcia, E., Robles-Cardona, N. and Fradera, J. (1985) Kaposi's sarcoma in transfusion-associated AIDS. N Eng J Med, 312, 648.
Verdonck, L. F., Graan-Hentzen, Y. C., Dekker, A. W., et al. (1987) Cytomegalovirus seronegative platelets and leukocyte poor red blood cells can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant, 2, 73–8.
Waner, J. L., Weller, T. H. and Kevy, S. V. (1973) Patterns of cytomegalovirus complement fixing antibody activity: a longitudinal study of blood donors. J Infect Dis, 127, 538–43.
Wenz, B. and Burns, E. R. (1991) Phenotypic characterization of white cells in white cell reduced red cell concentrate using flow cytometry. Transfusion, 31, 829–35.
Wilhelm, J. A., Matter, L. and Schopfer, K. (1986) The risk of transmitting cytomegalovirus to patients receiving blood transfusion. J Infect Dis, 154, 169–71.
Winston, D. J., Ho, W. G., Howell, C. L., et al. (1980) Cytomegalovirus infections associated with leukocyte transfusions. Ann Intern Med, 93, 671–5.
Winston, D. J., Huang, E. S., Miller, M. J., et al. (1985) Molecular epidemiology of cytomegalovirus infections associated with bone marrow transplantation. Ann Intern Med, 102, 16–20.
Wong, E. C., and Luban, L. N. (2002) Cytomegalovirus and parvovirus transmission by transfusion. In Rossi's Principles of Transfusion Medicine, 3rd edn, eds Simon, T. L., Dzik, W. H., Snyder, E. L., Stowell, C. P. and Strauss, R. G., pp. 757–71. Philadelphia, PA, Lippincott Williams & Wilkins.
Yamanishi, K., Okuno, T., Shiraki, K., et al. (1988) Identification of human herpes virus 6 as a causal agent for exantherm subitum. Lancet, 1, 1065–67.
Yeager, A. S., Grumet, F. C., Hafleigh, E. B., et al. (1981) Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J. Pediatr, 98, 281–7.
Zerr, D. M., Gooley, T. A., Yeung, L., et al. (2001) Human herpes virus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients. Clin Infect Dis, 33, 763–71.
Zerr, D. M., Meier, A. S., Selke, S. S., et al. (2005) A population-based study of primary human herpes virus 6 infection. N Eng J Med, 352, 768–76.
Zhanghellini, F., Boppana, S. B., Emery, V. C., et al. (1999) Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis, 180, 702–7.